GlassScriptPhysician profile
Howard N Garson
NPI 1154316826
$5,369.82
in general payments reported to CMS, 2019-2025
29 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $234 · 2021: $162 · 2022: $292 · 2023: $860 · 2024: $1,379 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,471.74 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $788.47 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $726.43 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $515.46 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $281.31 | 2019-2025 | |
| Braintree Laboratories, INC. | $195.75 | 2021-2025 | Suflave |
| Phathom Pharmaceuticals, INC. | $193.93 | 2024-2025 | Voquezna |
| Celgene Corporation | $145.24 | 2019-2024 | Zeposia |
| Ardelyx, INC. | $142.08 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $131.78 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $111.08 | 2020-2024 | |
| Boston Scientific Corporation | $71.77 | 2019-2022 | |
| Daiichi Sankyo INC. | $54.92 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $54.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $49.42 | 2023-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $48.28 | 2019-2024 | Rebyota |
| Allergan, INC. | $44.14 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $42.47 | 2019-2020 | |
| Madrigal Pharmaceuticals | $36.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $20.07 | 2025 | Wegovy |
| Genzyme Corporation | $19.70 | 2024 | |
| Exact Sciences Corporation | $18.76 | 2025 | Cologuard Collection Kit |
| Covidien LP | $16.53 | 2019 | |
| Celltrion USA INC. | $15.86 | 2025 | Vegzelma |
| Capsovision, INC. | $15.33 | 2024 | Capsocam Plus |
| Cook Medical LLC | $15.16 | 2021 | |
| Shire North American Group INC | $14.30 | 2019 | |
| Ucb, INC. | $13.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Garson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.